How it works: Removing B cells →

Uplizna

EU: Approved in the EU since 2022US: FDA approved 2020

Molecule type
Antibody
Mechanism (ChEMBL)
B-lymphocyte antigen CD19 binding agent
Targets
B-lymphocyte antigen CD19
Availability
Authorised in all EU and EEA countries. Reimbursement is decided by each country.

Approvals

  • USUplizna · Approved2020-06-11 Source
  • EU/EEAUplizna · Authorised2022-04-25 Source

Safety communications

None recorded.

Most-reported side effects (FDA reports)

Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.

113 reports in total, 102 marked serious.

  • Off label use34
  • Neuromyelitis optica spectrum disorder33
  • Urinary tract infection11
  • Pneumocystis jirovecii pneumonia9
  • Infection8
  • Pneumonia8
  • Infusion related reaction7
  • Pyrexia7
  • Upper respiratory tract infection6
  • Anaemia5

Trials

Key trials

Large trials with a reported result on their main goal.

Running now

Other trials (5)

Completed small trials, dose-finding studies and trials in other diseases.

For information only, not medical advice. Talk to your neurologist before changing treatment.

Hypotheses involving this medicine

Loading hypotheses…

Loading reviews and guidelines…

Lab studies

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error